TY - JOUR
T1 - Effects of L-carnitine supplementation on muscular symptoms in hemodialyzed patients
AU - Sakurauchi, Yasuhiro
AU - Matsumoto, Yoshihiro
AU - Shinzato, Toru
AU - Takai, Ichiro
AU - Nakamura, Yutaka
AU - Sato, Motoyoshi
AU - Nakai, Shigeru
AU - Miwa, Masamiki
AU - Morita, Hiroyuki
AU - Miwa, Toshihiko
AU - Amano, Izumi
AU - Maeda, Kenji
PY - 1998/8
Y1 - 1998/8
N2 - Various muscle symptoms are well recognized among patients on maintenance hemodialysis. Carnitine deficiency may be an important factor of dialysis-associated muscle symptoms, whereas high-dose L-carnitine supplementation may result in unphysiologically high plasma levels of carnitine and carnitine esters. We studied the effect of low-dose L-carnitine treatment (500 mg/d) on muscle symptoms, plasma carnitine fractions, and lipid profiles in 30 periodically dialyzed patients with muscular weakness, fatigue, or cramps/aches. After 12 weeks of L-carnitine treatment, about two- thirds of patients had at least some improvement in muscular symptoms, whereas carnitine fractions were normal or slightly above normal ranges, but lipid profiles showed no demonstrable changes. This study also showed the correlation between plasma-free carnitine deficiency and months on dialysis. These results suggest that prolonged low-dose L-carnitine treatment can improve dialysis-associated muscle symptoms by restoring carnitine tissue levels and washing out acyl moieties.
AB - Various muscle symptoms are well recognized among patients on maintenance hemodialysis. Carnitine deficiency may be an important factor of dialysis-associated muscle symptoms, whereas high-dose L-carnitine supplementation may result in unphysiologically high plasma levels of carnitine and carnitine esters. We studied the effect of low-dose L-carnitine treatment (500 mg/d) on muscle symptoms, plasma carnitine fractions, and lipid profiles in 30 periodically dialyzed patients with muscular weakness, fatigue, or cramps/aches. After 12 weeks of L-carnitine treatment, about two- thirds of patients had at least some improvement in muscular symptoms, whereas carnitine fractions were normal or slightly above normal ranges, but lipid profiles showed no demonstrable changes. This study also showed the correlation between plasma-free carnitine deficiency and months on dialysis. These results suggest that prolonged low-dose L-carnitine treatment can improve dialysis-associated muscle symptoms by restoring carnitine tissue levels and washing out acyl moieties.
UR - http://www.scopus.com/inward/record.url?scp=13144307082&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=13144307082&partnerID=8YFLogxK
U2 - 10.1053/ajkd.1998.v32.pm9708610
DO - 10.1053/ajkd.1998.v32.pm9708610
M3 - Article
C2 - 9708610
AN - SCOPUS:13144307082
SN - 0272-6386
VL - 32
SP - 258
EP - 264
JO - American Journal of Kidney Diseases
JF - American Journal of Kidney Diseases
IS - 2
ER -